First Tracks Biotherapeutics, Inc.First Tracks Biotherapeutics, Inc.
TRAXFirst Tracks Biotherapeutics, Inc. engages in the research and development of immunology therapeutics for autoimmune and inflammatory diseases. It focuses on clinical-stage programs for rosnilimab, ANB033 and ANB101. The company is headquartered in San Diego, CA.
Market cap
$1.1BNo data
Revenue
No dataNo data
Net income
No dataNo data
Free cash flow
No dataNo data
Current assets substantially exceed short-term liabilities, providing ample near-term liquidity. Return on invested capital is dramatically more negative than already negative ROA and ROE, while growth and profitability measures are unavailable.
As of 2026-06-30Market
Listed stock
TRAXPriceNasdaqLoading…Loading…1Y